1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,17-Hexadecahydrocyclopenta[a]phenanthren-16-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,17-Hexadecahydrocyclopenta[a]phenanthren-16-one
• 英文别名: 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,17-hexadecahydrocyclopenta[a]phenanthren-16-one
• 化学式: C₁₇H₂₆O
• 分子量: 246.4
• InChiKey: VVZZCVZROAMMFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：Sphaera Pharma Pvt. Ltd.

  公开号：EP2948152A2

  公开（公告）日：2015-12-02
• [EN] NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION<br/>[FR] NOUVEAUX COMPOSÉS DE 11BÊTA-HYDROXY-STÉROÏDES DESTINÉS À ÊTRE UTILISÉS UTILISATION DANS LA BIOGENÈSE DE MITOCHONDRIES ET LES MALADIES ASSOCIÉES AVEC LA DYSFONCTION OU LA DÉPLÉTION MITOCHONDRIALE
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2014115167A2

  公开（公告）日：2014-07-31

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.
• [EN] (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] COMPOSITIONS D'UNDÉCANOATE DE (17-Β)-3-OXO-ANDROST-4-ÉN -17-YLE, ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI
  申请人：LIPOCINE INC

  公开号：WO2016033611A1

  公开（公告）日：2016-03-03

  Disclosed herein are compositions having a lipophilic active agent and methods of their use. This invention further discloses substantially pure (17-beta)-3-0xoandrost-4-en-17-yl undecanoate includes (17-beta)-3-0xoandrost-4-en-17-yl undecanoate substantially free of synthetic impurities, decomposition impurities or both.
• [EN] (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] COMPOSITIONS DE (17-SS)-3-OXOANDROST-4-ÈN-17-YL TRIDÉCANOATE ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：LIPOCINE INC

  公开号：WO2016033549A2

  公开（公告）日：2016-03-03

  Described here are substantially pure (17-?)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof